A small-molecule drug used in CAMH-led preclinical studies has shown promise as a potential new MS treatment. The outcomes have been distributed in the journal Science Advances. Developing Dr. Tooth Liu's prior work that distinguished a clever medication focus for the treatment of MS, she and her group have now made a little particle compound that is powerful in two different creature models of MS. This addresses a key progression that brings this MS research closer to the facility to influence patient consideration. MS is a neurological disease that progresses over time and has no cure at this time. It